Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide explicit details on the current or expected order book or pending orders in precise figures. The company mentions a portfolio of projects across various phases: 41 projects in Phase-II and 2 in Phase-III, with ongoing churning as about 30 to 40 molecules exit and new ones enter annually. They have visibility of about six months on project progress, indicating limited forecasting ability for order pipelines. The company is filing 10 ANDAs over the next 4-5 years targeting products going off-patent in 2-3 years, expected to generate net profits of USD 2-3 million

Any current/future new fundraising through debt or equity?

There is no direct mention of any current or planned fundraising through debt or equity in the provided transcript. The company appears to be utilizing spare capital by investing in mutual funds rather than raising new funds. Capital expenditure plans include a Rs.120 crore investment for a new block at Pashamylaram, implying internal funding rather than new external fundraising. The company focuses on leveraging existing infrastructure to manage costs, indicating cautious capital management without reliance on fresh capital raising. No explicit plans or indications of new debt or equity issua

Future growth expectations in sales/revenue/volumes?

Suven Life Sciences expects a 10% to 15% growth in topline (revenue) and bottom-line (profits) going forward. The CRAMS business growth is linked more to the success of molecules moving through clinical phases than just the number of projects, which typically churns with 30-40 molecules leaving and joining annually. Specialty Chemicals is expected to have minimal growth, around ±5% annually, as it is a mature product line. The launch quantities for commercial molecules are anticipated to exceed previous guidance (around Rs. 60-70 crore annually). Continued investment in NCE (New Chemical Entit

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a growth rate of around 10% to 15% in topline and bottom-line (PAT), maintaining similar margins. For the current fiscal year, revenue guidance is Rs. 60-70 crore from commercialized molecules, with potential to exceed this. Operational profits may grow modestly as R&D expenses increase marginally, reflecting ongoing clinical trials and development costs. Specialty Chemicals segment is expected to remain stable with about ±5% growth, as it comprises mature products. The launch of new NCE (New Chemical Entity) pipeline molecules each year adds long-term value but wit

Suven Life Sciences LtdQ1 FY18Healthcare Services

Suven Life Sciences Ltd Q1 FY18 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹308Market Cap: ₹9.5K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Suven Life Sciences expects a 10% to 15% growth in topline (revenue) and bottom-line (profits) going forward.
The CRAMS business growth is linked more to the success of molecules moving through clinical phases than just the number of projects, which typically churns with 30-40 molecules leaving and joining annually.
Specialty Chemicals is expected to have minimal growth, around ±5% annually, as it is a mature product line.
The launch quantities for commercial molecules are anticipated to exceed previous guidance (around Rs. 60-70 crore annually).
Continued investment in NCE (New Chemical Entities) is expected to mature over time, adding value.
No visibility beyond six months on clinical timelines and commercial ramp-ups, leading to cautious yet positive growth outlook.
Infrastructure expansion supports leveraging existing assets without major capital increases, indicating scalability with current resources.

Margin guidance

Category 3

The company expects a growth rate of around 10% to 15% in topline and bottom-line (PAT), maintaining similar margins.
For the current fiscal year, revenue guidance is Rs. 60-70 crore from commercialized molecules, with potential to exceed this.
Operational profits may grow modestly as R&D expenses increase marginally, reflecting ongoing clinical trials and development costs.
Specialty Chemicals segment is expected to remain stable with about ±5% growth, as it comprises mature products.
The launch of new NCE (New Chemical Entity) pipeline molecules each year adds long-term value but with inherent risk; blockbuster success is not promised but potential exists.
R&D expenses are expected to have a marginal increase, mainly for ongoing trials like SUVN-502 and new initiatives like 911 trial.
Tax expenses will move to normal levels (~30-34%) due to reduced weighted deductions, impacting net profit accordingly.

See what Suven Life Sciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no direct mention of any current or planned fundraising through debt or equity in the provided transcript.
The company appears to be utilizing spare capital by investing in mutual funds rather than raising new funds.
Capital expenditure plans include a Rs.120 crore investment for a new block at Pashamylaram, implying internal funding rather than new external fundraising.
The company focuses on leveraging existing infrastructure to manage costs, indicating cautious capital management without reliance on fresh capital raising.
No explicit plans or indications of new debt or equity issuance are discussed in this call.

Order book

The transcript does not provide explicit details on the current or expected order book or pending orders in precise figures.
The company mentions a portfolio of projects across various phases: 41 projects in Phase-II and 2 in Phase-III, with ongoing churning as about 30 to 40 molecules exit and new ones enter annually.
They have visibility of about six months on project progress, indicating limited forecasting ability for order pipelines.
The company is filing 10 ANDAs over the next 4-5 years targeting products going off-patent in 2-3 years, expected to generate net profits of USD 2-3 million per product.
There is commercial supply visible (approx Rs. 25 crore in the quarter) and guidance for Rs. 60-70 crore revenue in CRAMS business this year, possibly exceeding that.
Overall, the orderbook appears dynamic but growing at a steady rate of approximately 10-15% annually.

See what Suven Life Sciences Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

- Rs. 120 crore CAPEX planned for creation of a new specialty chemicals block at Pashamylaram, meeting OEL4 requirements (Page 12). - Maintenance CAPEX expected to be Rs. 20-25 crore, roughly 10-15% of regular requirements (Page 12). - Rs. 100 crore investment towards expansion for increased API production capacity from 7.5 tonnes to 75 tonnes per month through phased environmental clearance (Pages 10). - Expansion permissions already obtained for maximum capacity based on plot limits to avoid future licensing needs (Page 10). - Regular CAPEX additions ongoing, in addition to previous Vizag Specialty Chemicals facility capitalization (Page 8). - The R&D infrastructure created is leveraged for new generic ANDA filings; any incremental costs are mostly recurring expenditures (Page 16). Overall, significant capital investment is underway primarily for specialty chemicals facility expansion and infrastructure to support growth in NCE and generic pipelines.

Track Suven Life Sciences Ltd — get its next earnings analysis in your feed

How does Suven Life Sciences Ltd rank vs peers in Healthcare Services?

Pro feature

ThisSuven Life Sciences Ltd

Rev 3Mar 3

See where Suven Life Sciences Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Suven Life Sciences Ltd rank in Healthcare Services?

Compare Suven Life Sciences Ltd against every Healthcare Services company (Q1 FY18) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Suven Life Sciences Ltd's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
3B Blackbio DX Ltd (Q4 FY24)
41% increase). Key concall takeaways from 3B Blackbio DX Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Suven Life Sciences Ltd Q1 FY18 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Suven Life Sciences Ltd rank in Healthcare Services?

Continue your research

What Suven Life Sciences Ltd's management said in earlier quarters

Others in Healthcare Services this season